Clinical Trial Update: Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

View source ↗

Summary

A multicenter study is evaluating an 18F-labeled PET imaging agent (NY104) for renal cell carcinoma imaging, currently in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• 18F-Labeled NY104

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Status: RECRUITING